semaglutide 1 month results 3 Semaglutide Before and After

FDA Crackdown on Compounded GLP-1s (Regulatory): On February 6, 2026, the FDA announced a formal intent to restrict the use of active pharmaceutical ingredients (APIs) for non-approved compounded GLP-1 drugs, targeting "mass-marketed" alternatives from companies like Hims & Hers as the national supply of brand-name versions stabilized

This approach holds promise for investigating the reduction of dosage of drugs with severe side effects and developing research compounds tailored to specific disease states

The 90-Day Guarantee Language Requires Written Clarification WellMedr's marketing materials reference a 90-day money-back guarantee

Published trials show up to 70% increases in collagen output in vitro and significant improvements in skin density in 12-week human clinical studies